Lantheus Holdings, Inc. (LNTH) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 1 fund trimming or exiting versus the previous quarter. 0 members of Congress reported 0 purchases vs 2 sales. Latest close $102.00 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Deerfield Management · First Eagle Investment Management — 2 tracked funds hold LNTH. See all holders.
0 members of Congress reported buying (0 purchases vs 2 sales). Politician trading
IDEXX LABORATORIES INC /DE (IDXX) · Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Deerfield Management | 0.87% | 752,999 | TRIMMED (-9.1%) Q3 filed Nov 16 |
| First Eagle Investment Management | <0.01% | 8,000 | NEW Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -6.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 466 of 8,857 filers |
| Long-only filers among them | 464 |
| Change vs 2026 Q1 | +71 net · 446 entered · 375 exited |
| Shares reported, all filers | 75,159,277 |
| Reported value, all filers | $8.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances (SIC 2835) |
| Revenue · FY2025 | $1.5B |
| Net income · FY2025 | $233.6M |
| Total assets · FY2025 | $2.2B |
| Shares outstanding | 65,272,369 |
| Market cap (at latest close) | $6.7B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Oct 15, 2026 | 3,632,323 |
| Share of shares outstanding | 5.56% |
| Days to cover | 4.48 |
Shares short at recent settlements — Jul 31, 2026: 6.3M · Aug 14, 2026: 5.1M · Aug 31, 2026: 4.2M · Sep 15, 2026: 4.0M · Sep 30, 2026: 3.8M · Oct 15, 2026: 3.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 24K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | Blanchfield Paul | Former Officer | 6,713 | $449.6K | Feb 2, 2026 | SEC filing |
| Jan 6, 2026 | Blanchfield Paul | Former Officer | 7,217 | $501.8K | Jan 6, 2026 | SEC filing |
| Dec 12, 2025 | Blanchfield Paul | Officer | 3,265 | $218.2K | Dec 12, 2025 | SEC filing |
| Nov 26, 2025 | Blanchfield Paul | Former Officer | 11,776 | $686.7K | Nov 26, 2025 | SEC filing |
| Nov 14, 2025 | Blanchfield Paul | Former Officer | 16,530 | $871.1K | Nov 14, 2025 | SEC filing |
| Aug 13, 2025 | Blanchfield Paul | Officer | 3,060 | $163.9K | Aug 13, 2025 | SEC filing |
| Jun 13, 2025 | Niedzwiecki Daniel | Officer | 6,000 | $472.4K | Jun 13, 2025 | SEC filing |
| Jun 9, 2025 | Marshall Robert J. Jr. | Officer | 39,773 | $3.2M | Jun 9, 2025 | SEC filing |
| Jun 9, 2025 | McHugh Julie | Director | 5,192 | $423.8K | Jun 9, 2025 | SEC filing |
| Jun 5, 2025 | Heino Mary Anne | Director | 26,066 | $2.0M | Jun 2, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Farallon Capital Management, L.L.C. | SC 13G/A | 5,583,479 | 8.6% | Jun 30, 2026 | SEC filing |
| Jul 31, 2026 | Vanguard Portfolio Management | SC 13G | 3,300,293 | 5.1% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | JANUS HENDERSON GROUP PLC | SC 13G/A | 4,774,841 | 7.4% | Mar 31, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 3,421,414 | 5.2% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | JANUS HENDERSON GROUP PLC | SC 13G/A | 5,707,247 | 8.6% | Dec 31, 2025 | SEC filing |
| Feb 12, 2026 | Morgan Stanley | SC 13G/A | 1,640,837 | 2.5% | Dec 31, 2025 | SEC filing |
| Feb 5, 2026 | Farallon Capital Partners, L.P. | SC 13G/A | 420,581 | 0.6% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | JANUS HENDERSON GROUP PLC | SC 13G/A | 6,684,737 | 9.8% | Sep 30, 2025 | SEC filing |
| Nov 12, 2025 | Farallon Capital Partners, L.P. | SC 13G/A | 278,896 | 0.4% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
0 members of Congress reported buying (0 purchases vs 2 sales).
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Cisneros, Gilbert | House | D | 0 | 2 | Oct 15, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 91 Lobbying Disclosure Act filings named this company as client, 2010–2026; most common issues: Medicare/Medicaid (48), Health Issues (33), Energy/Nuclear (14).
Federal contracts: $143.5M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $781.6K |
| FY2022 | $13.4M |
| FY2023 | $26.8M |
| FY2024 | $27.3M |
| FY2025 | $34.9M |
| FY2026 | $40.4M |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C24622P0024 | Department of Veterans Affairs | $379.8K | Oct 1, 2021 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Key figures
· Growth — Latest revenue: $1.5B · 5-yr revenue CAGR: 35.4% · Straight growth years: 5
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.45 · Operating cash flow: $390.1M · Net income: $233.6M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold LNTH — ranked by lift, the co-holding pattern described in Methodology: IDEXX LABORATORIES INC /DE (IDXX) · Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 10, 2026 | 8.01 Other Events | SEC filing |
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 22, 2026 | 8.01 Other Events | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
IDEXX LABORATORIES INC /DE (IDXX) · Track Record: how the signals scored · Practice timing on LNTH
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.